QS Pharma, LLC

Primary Objectives: To characterize the effect of bexotegrast versus placebo on the change in forced vital capacity (FVC) at week 52 in subjects with idiopathic pulmonary fibrosis (IPF). Secondary Objectives: 1. To characterize the effect of bexotegrast versus placebo on disease progression during the 52-week treatment period. 2. To characterize the effect of bexotegrast versus placebo on the change in FVC at week 52 in subjects with IPF who did and did not receive background therapy at baseline. 3. To characterize the effect of bexotegrast versus placebo on improvement in global symptoms and function in IPF after 52 weeks of treatment. 4. To characterize the effect of bexotegrast versus placebo on changes in lung fibrosis at week 52 using high-resolution computed tomography (HRCT). 5. To characterize the safety and tolerability of bexotegrast versus placebo in subjects with IPF during the 52-week treatment period.

Primary objective: To evaluate the efficacy of seraceptinib by evaluating the rwORR in Chinese patients with advanced or metastatic RET gene fusion-positive thyroid cancer. Secondary objective: To evaluate the efficacy of seraceptinib by evaluating the rwPFS, rwDoR and rwDCR in Chinese patients with advanced or metastatic RET gene fusion-positive thyroid cancer. Exploratory objective: To describe the safety profile of seraceptinib. To investigate the treatment pattern of seraceptinib in real-world diagnosis and treatment routine

Phase Ib trial: Select the Phase II recommended dose of GH509.